Strategic window drives Microcide
Until now, antibiotics have been the terrain of the pharmaceutical giants, a terrain they have dominated by developing successive generations of broad spectrum antibiotics.
But like all large organizations, pharmaceutical companies tend to ignore business opportunities that can't meet their high hurdles for market size. As a result, they may miss chances to enter new research areas.
Start-up Microcide Inc. is challenging that dominance with an opportunistic strategy aimed at showing not only that a biotech company can move faster